

17 August 2021

ASX Market Announcements Office
Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Interim Financial Report, Appendix 4D and Outlook

Attached for release is the Doctor Care Anywhere Group PLC Interim Financial Report and Appendix 4D for the Half Year Ended 30 June 2021.

Outlook

The Company previously reported that Consultations for 2Q 2021 were steady at 89,400, up 69.3% on 2Q 2020 but down 1.3% on prior quarter (1Q 2021: 90,500) due to temporary GP supply constraints as a result of the UK vaccination programme which prevented the Company from provisioning sufficient capacity to meet demand.

Pleasingly, having executed a significant GP recruitment drive through 2Q 2021, we have seen a return to positive growth in consultations. In July a new record was set, with over 35,000 consultations delivered. We expect this momentum to continue through August and September and re-iterate our confidence of achieving our guidance of at least 100% revenue growth above FY 2020.

Dan Curran

Chief Financial Officer and Company Secretary
Doctor Care Anywhere Group PLC

This ASX announcement was authorised for release by the Board of Directors.

About Doctor Care Anywhere:

Doctor Care Anywhere is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence based pathways on its proprietary platform. DOC utilises its relationships with health insurers, healthcare providers and corporate customers to connect with patients to deliver a range of telehealth services.

Further Information:

Roger Newby

Domestique Consulting – Investor Relations +61 401 278 906



Interim Report **For the six months ended 30 June 2021**

Doctor Care Anywhere Group PLC
(Company Number 08915336)
(ARBN 645 163 873)



Contents

Appendix 4D – Half Year Report 1
Directors’ Report 2
Unaudited Interim Condensed Consolidated Financial Statements 5
Notes to the Interim Condensed Consolidated Financial Statements 9
Directors’ Declaration 19
Independent Review Report to Doctor Care Anywhere Group PLC 20
Corporate Directory 21



Appendix 4D – Half Year Report

Doctor Care Anywhere Group PLC Six month period ended 30 June 2021

Reporting period

Current reporting period (“1H21”): 1 January 2021 to 30 June 2021.

Previous corresponding period (“1H20”): 1 January 2020 to 30 June 2020.

Basis of preparation

This Appendix 4D has been prepared in accordance with measurement and recognition (but not disclosure) requirements of IFRS.

The financial information on which this report is based has been reviewed by Grant Thornton UK LLP.

Results for announcement to the market

		1H21	1H20	Variance	%
Revenue	£m's	11.2	4.6	6.6	143.5%
Net loss	£m's	(8.0)	(18.7)	10.7	57.2%
Net tangible assets per security	£'s	0.10	(1.38)	1.48	107.2%

Revenue

Revenue growth across the period was driven by an increased volume of consultations delivered to DOC's growing bases of Eligible and Activated Lives.

Net loss

Net loss for 1H20 includes two exceptional items which contribute significantly towards the variance in net loss between periods. The exceptional items were as follows:

- Fair value finance charges in respect of Convertible Loan Notes issued by DOC, such charges totalling £18.5 million in 1H20; and
- Other Operating Income generated in respect of the Company's partial disposal of Doctor at Hand Diagnostics Limited to AXA Health, such income totalling £5.0 million in 1H20.

Adjusting for these items, 1H21 net losses increased by £2.8 million (53.8%) above 1H20. These increases were driven by increased investment by the Company in its Research & Development and Sales & Marketing capabilities to drive business growth, in addition to increased Share Based Payment and General & Administration expenses to support the growing business.

Net tangible assets per security

The Company was in a net liability position at the end of 1H20 due to outstanding Convertible Loan Notes, the conversion of these notes and funds raised at the Company's IPO in December 2020 drove the variance in net tangible assets per security.

Dividends

It is not proposed to pay any dividends, nor were any paid in the prior period.

Joint Ventures

The Company is party to a joint venture with AXA Health. The Company holds 50% of the issued share capital of Doctor at Hand Diagnostics Limited, with AXA Health holding the other 50%.

Directors' Report

The Directors present the condensed consolidated interim financial report of Doctor Care Anywhere Group PLC ("the Company" or "Doctor Care Anywhere") and its subsidiaries ("the Group") for the half year ended 30 June 2021 ("1H21").

The names of the Directors and Officers in office during the half-year reporting period 1 January 2021 – 30 June 2021 and as at the date of this report are shown below:

- Jonathan Baines Chairman and Executive Director
- Dr Bayju Thakar Chief Executive Officer and Managing Director
- Romana Abdin Independent Non-Executive Director
- Simon Calver Non-Executive Director
- Richard Dammary Independent Non-Executive Director
- David Ravech Non-Executive Director
- Leanne Rowe Independent Non-Executive Director
- Vanessa Wallace Independent Non-Executive Director
- Dan Curran Chief Financial Officer & Company Secretary

2021 Half Year Highlights

- 558,700 Activated Lives¹ at 30 June 2021, up 90.0% on 30 June 2020
- 179,900 GP Consultations conducted in 1H21, up 131.0% on 1H20
- Unaudited Revenue of £11.2 million in 1H21, up 143.5% on 1H20
- Cash position of £31.5 million at 30 June 2021
- Service launched with new channel partner Allianz
- Partnership with Nuffield Health to be strengthened through launch of new integrated virtual and in-person GP service
- Mental Health proposition launched with new channel partner, business service broker Partners&
- 2021 full year revenue guidance issued, revenue to grow at least 100% above 2020

About Doctor Care Anywhere

Doctor Care Anywhere is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence based pathways on its proprietary platform. Doctor Care Anywhere utilises its relationships with health insurers, healthcare providers and corporate customers to connect with patients to deliver a range of telehealth services.

Doctor Care Anywhere is listed on the Australian Securities Exchange (ASX:DOC).

Operating and Financial Review

000's	1H21	2H20	Variance	%
Eligible lives ²	2,357.1	2,221.8	135.3	6.1%
Activated lives	558.7	432.5	126.2	29.2%
Consultations	179.9	136.9	43.0	31.4%

The Company saw pleasing growth across key operating metrics during 1H21. Activated Lives grew to 558,700 at 30 June 2021, an increase of 126,200 (29.2%) above 31 December 2020. Growth in Activated Lives was driven by marketing activities across Doctor Care Anywhere's 2.4 million Eligible Lives and organic demand for the Company's services.

With demand growing across the period, 179,900 GP consultations were delivered during 1H21, an increase of 43,000 (31.4%) above 2H20. Growth in GP consultations was driven by the increased number of Activated Lives.

1 **Activated Lives** represents the total number of people who "sign up" for Doctor Care Anywhere's service and enter their personal details.

2 **Eligible Lives** represents the total number of people who have an entitlement to use DOC's services.

Summary of 1H21 Consolidated Statement of Comprehensive Income

£ in millions	1H21	2H20	Variance	%
Utilisation revenue	8.3	5.9	2.4	40.7%
Subscription revenue	0.9	1.0	(0.1)	(10.0%)
Other revenue	2.0	0.2	1.8	900.0%
Revenue	11.2	7.1	4.1	57.7%
Cost of sales	(5.4)	(3.8)	(1.6)	(42.1%)
Gross profit	5.8	3.3	2.5	75.8%
<i>Gross profit margin</i>	<i>51.8%</i>	<i>46.5%</i>	<i>5.3%</i>	<i>11.4%</i>
<i>Underlying gross profit margin</i>	<i>41.3%</i>	<i>44.9%</i>	<i>(3.6%)</i>	<i>(8.1%)</i>
Operating costs	(2.4)	(1.9)	(0.5)	(26.3%)
Contribution	3.4	1.4	2.0	142.9%
<i>Contribution margin</i>	<i>30.4%</i>	<i>19.7%</i>	<i>11.7%</i>	<i>59.3%</i>
<i>Underlying contribution margin</i>	<i>15.2%</i>	<i>17.4%</i>	<i>(1.5%)</i>	<i>(8.6%)</i>
Sales and marketing	(1.6)	(1.0)	(0.6)	(60.0%)
Research and development	(2.2)	(1.4)	(0.8)	(57.1%)
General and administration	(6.7)	(6.2)	(0.5)	(8.1%)
Other operating income	0.3	1.0	(0.7)	(70.0%)
Share based payment	(0.6)	(2.2)	1.6	72.7%
Share of JV net loss	(0.1)	(0.7)	0.6	85.7%
EBITDA	(7.5)	(9.1)	1.6	17.6%
Depreciation and amortisation	(0.5)	(0.4)	(0.1)	(25.0%)
EBIT	(8.0)	(9.5)	1.5	15.8%
Finance income/(expense)	(0.1)	(3.2)	3.1	96.9%
Loss before tax	(8.1)	(12.7)	4.6	36.2%
Tax	0.1	–	0.1	–
Loss after tax	(8.0)	(12.7)	4.7	37.0%

Notes:

- **Utilisation revenue:** represents revenue from the provision of telehealth services. Customers are charged per consultation performed or billable cancelled consultation.
- **Subscription revenue:** represents revenue from monthly and annual service subscriptions. Revenue is driven by the number of subscription-based Eligible Lives.
- **Other revenue:** consists of underwrite top-up payments which arise when a customer agrees to purchase a certain number of consultations and there is a shortfall between the pre-agreed and actual consultation volumes. Other revenue also includes technology platform licence fees and digital design services fees.
- **Cost of sales:** consists of salaries and other related costs of the doctors who deliver telehealth services to customers.
- **Other operating income:** primarily represents recharges to the Company's Joint Venture with AXA Health.
- **Share based payment:** relates to non-cash remuneration in the form of share options and share awards granted to the Company's Executive Directors, employees and suppliers.
- **Share of JV net loss:** represents the Company's 50% share of net losses generated by its JV with AXA Health.
- **Net finance income/(expense):** primarily relates to finance charges in respect of the fair value adjustment of Convertible Loan Notes issued by the Company.
- **Tax:** relates to tax credits claimed for qualifying research and development expenses.

Directors' Report cont.

Unaudited Revenue in 1H21 was £11.2 million, up £4.1 million (57.7%) on 2H20. This is inclusive of £2.0 million of one-off items recognised in 1H21. Underlying Revenue³ in 1H21 was £9.2 million, up £2.3 million (33.3%) on 2H20. Underlying Revenue growth was predominantly driven by the increase in the number of GP consultations delivered during the period.

Gross Profit in 1H21 was £5.8 million, up £2.5 million (75.8%) on 2H20. Underlying Gross Profit³ in 1H21 was £3.8 million, up £0.7 million (22.6%) on 2H20.

Operating costs in 1H21 were £2.4 million, up £0.5 million (26.3%) on 2H20. This growth was predominantly driven by increased headcount in the Patient Experience team, who are responsible for managing administrative tasks in respect of the Company's service delivery.

Contribution in 1H21 was £3.4 million, up £2.0 million (142.9%) on 2H20. Underlying Contribution³ in 1H21 was £1.4 million, up £0.2 million (16.7%) on 2H20.

Sales and Marketing costs in 1H21 were £1.6 million, a £0.6 million (60.0%) increase on 2H20. This growth was predominantly driven by increased headcount in the marketing team.

Research and Development costs in 1H21 were £2.2 million, a £0.8 million (57.1%) increase on 2H20. This increase was driven by increased investment in the development of new services and capabilities.

General and Administration costs in 1H21 were £6.7 million, up £0.5 million (8.1%) on 2H20.

Other Operating Income in 1H21 was £0.3 million, down £0.7 million (70.0%) on 2H20. This reduction was due to lower recharges to the Company's joint venture with AXA Health.

Share of Joint Venture Net Loss in 1H21 was £0.1 million, a £0.6 million (85.7%) improvement on 2H20. This reduction in losses was due to greater throughput to rebate generating diagnostic services.

EBITDA loss in 1H21 was £7.5 million, a £1.6 million (17.6%) improvement on 2H20.

Finance Expenses in 1H21 were £0.1 million, a £3.1 million (96.9%) reduction on 2H20. This reduction was due to fair value adjustments recognised in 2H20 in respect of conversion of convertible loan notes issued by the Company.

³ **Underlying Revenue, Underlying Gross Profit, Underlying Gross Profit Margin, Underlying Contribution and Underling Contribution Margin** exclude irregular revenue items such as underwritten volume top-up payments, technology platform licencing fees and digital design service fees. This metric is intended to give a clear view of the underlying operational performance of the business.

Unaudited Interim Condensed Consolidated Financial Statements

Prepared under International Accounting Standard 34
For the six months ended 30 June 2021

Interim Condensed Consolidated Statement of Comprehensive Income For the six months ended 30 June 2021

	Note	30 June 2021 Unaudited £'000	30 June 2020 Unaudited £'000
Revenue	3	11,238	4,572
Cost of sales		(5,421)	(2,047)
Gross profit		5,817	2,525
Administrative expenses	5	(13,948)	(7,514)
Other operating income	6	254	4,964
Operating loss	7	(7,877)	(25)
Share of loss of joint venture	13	(144)	(158)
Finance income		1	–
Finance costs	8	(72)	(18,540)
Loss before taxation		(8,092)	(18,723)
Tax credit	9	50	61
Loss for the financial period		(8,042)	(18,662)
Other comprehensive income		–	–
Total comprehensive loss for the year		(8,042)	(18,662)
Loss per share		£	£
Basic and diluted EPS	10	0.02	0.16

The notes on pages 9 to 18 form part of these interim condensed consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements cont.

Interim Condensed Consolidated Statement of Financial Position As at 30 June 2021

	Note	30 June 2021 Unaudited £'000	31 December 2020 Audited £'000
Non-current assets			
Property, plant and equipment	11	1,781	1,697
Intangible assets	12	4,194	3,580
Interest in joint venture	13	2,043	2,187
Total non-current assets		8,018	7,464
Current assets			
Trade and other receivables: due within one year	14	2,845	3,451
Corporation tax receivable		215	164
Cash at bank and in hand		31,472	38,362
Total current assets		34,532	41,977
Current liabilities			
Trade and other payables: due within one year	15	(4,567)	(3,776)
Total current liabilities		(4,567)	(3,776)
Non-current liabilities			
Trade and other payables: due after one year	16	(958)	(1,205)
Total non-current liabilities		(958)	(1,205)
Net assets		37,025	44,460
Capital and reserves			
Called up share capital		70	70
Share premium account		45,960	45,945
Capital redemption reserve		–	–
Other reserves		2,869	2,276
Profit and loss account		(11,874)	(3,831)
Total equity		37,025	44,460

The notes on pages 9 to 18 form part of these interim condensed consolidated financial statements.

Interim Condensed Consolidated Statement of Changes In Equity

For the six months ended 30 June 2021

For the six months ended 30 June 2021

	Called up share capital Unaudited £'000	Share premium account Unaudited £'000	Capital redemption reserve Unaudited £'000	Other reserves Unaudited £'000	Accumulated Losses Unaudited £'000	Total equity Unaudited £'000
At 1 January 2021	70	45,945	–	2,276	(3,832)	44,459
Comprehensive loss for the period	–	–	–	–	(8,042)	(8,042)
Total comprehensive loss for the period	–	–	–	–	(8,042)	(8,042)
Shares issued during the period	–	15	–	–	–	15
Share based payments	–	–	–	593	–	593
At 30 June 2021	70	45,960	–	2,869	(11,874)	37,025

For the six months ended 30 June 2020

	Called up share capital Unaudited £'000	Share premium account Unaudited £'000	Capital redemption reserve Unaudited £'000	Other reserves Unaudited £'000	Accumulated Losses Unaudited £'000	Total equity Unaudited £'000
At 1 January 2020	20	14,705	2	99	(20,180)	(5,354)
Comprehensive loss for the period	–	–	–	–	(18,662)	(18,662)
Total comprehensive loss for the period	–	–	–	–	(18,662)	(18,662)
Share based payments	–	–	–	2	–	2
At 30 June 2020	20	14,705	2	101	(38,842)	(24,014)

The notes on pages 9 to 18 form part of these interim condensed consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements cont.

Interim Condensed Consolidated Statement of Cash Flows For the six months ended 30 June 2021

	Note	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Cash flows from Operating Activities			
Receipts from customers		12,285	3,328
Payments to suppliers and employees		(17,479)	(7,424)
Finance income received		1	–
Finance cost paid		(1)	(1)
Government grants and tax incentives		–	78
Total Cash flows from Operating Activities		(5,194)	(4,019)
Cash flows from Investing Activities			
Payment for property, plant and equipment		(365)	(158)
Purchase of intangible fixed assets		(905)	(580)
Proceeds from the disposals of entities	6	–	2,992
Repayment of third party loans		–	93
Total Cash flows from Investing Activities		(1,270)	2,347
Cash flows from Financing Activities			
Payments to suppliers in relation to equity issue		(111)	(172)
Proceeds from equity issue		15	–
Proceeds from issues of convertible loan notes		–	3,000
Repayment of loans		(276)	(189)
Total Cash flows from Financing Activities		(372)	2,639
Net Cash flows		(6,836)	967
Cash and cash equivalents at beginning of year		38,362	592
Effect of movement in exchange rates on cash held		(54)	–
Cash and cash equivalents at the end of year		31,472	1,559

The notes on pages 9 to 18 form part of these interim condensed consolidated financial statements.

The interim condensed financial statements were approved and authorised for issue by the board and were signed on its behalf by:



Dr Bayju Thakar

Chief Executive Officer and Managing Director

Date: 17 August 2021

Notes to the Interim Condensed Consolidated Financial Statements

For the six months ended 30 June 2021

1. Corporate information

Doctor Care Anywhere Group PLC (the 'Company') and its subsidiary undertakings (together referred to as the 'Group') are engaged in digital healthcare service and development.

Doctor Care Anywhere Group PLC is a public company limited by shares and registered in England and Wales, registered number 08915336. Its registered office is located at 13-15 Bouverie Street, 2nd Floor, London, England, EC4Y 8DP. It is listed on the Australian Securities Exchange (ASX:DOC).

2. Significant accounting policies

2.1 Basis of preparation

The unaudited interim condensed consolidated financial statements covers Doctor Care Anywhere Group PLC and the entities it controlled at the end of, or during, the half year ended 30 June 2021 (referred to as the 'Group'), and have been prepared in accordance with IAS 34, Interim Financial Reporting. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 for the year ended 31 December 2020.

2.2 New standards, interpretations and amendments adopted by the Group

There were no new standards effective as of 1 January 2021 and the group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Therefore the accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2020.

There has been a change in estimate to the assumed useful economic life over which capitalised software development costs are amortised, which is further explained below.

Software development costs

In prior periods, all capitalised software development costs were estimated to have a useful economic life of ten years and were amortised over this period on a straight line basis. From 1 January 2021, the useful economic life of individually identifiable elements of capitalised software development costs are assessed individually, this has resulted in assets being amortised over useful economic lives of between three and ten years.

In the past, the Directors considered a ten year useful economic life for capitalised software development costs to be appropriate in prior periods as the focus of development activities was predominantly on the core systems that would underpin the core internally developed software assets. However, during the current period the focus of software development activities has shifted to modular enhancements to the core platform, the useful economic life of which is not estimated to align to the core platform in all instances. The Directors consider that this change in estimate provides for more accurate representation of the useful economic life of capitalised software development assets.

2.3 Going concern

These financial statements have been prepared on a going concern basis, which assumes that the Group will continue to be able to meet its liabilities as they fall due for the foreseeable future, which is defined as a period of not less than twelve months from the signing of these accounts.

The Directors have prepared cash flow forecasts through to December 2022 to ensure the going concern criteria are met. Whilst there are inherent uncertainties in any forecasting exercise, in light of the significant cash resources on hand, even in severe but plausible events where the Group significantly underperforms against its forecast, it would have sufficient resources on hand to continue to meet its liabilities as they fall due, therefore the Directors have concluded that it is appropriate to continue to adopt the going concern basis of accounting in preparing these consolidated financial statements.

Notes to the Interim Condensed Consolidated Financial Statements cont.

3. Revenue

	Period ended 30 June 2021 £'000	Period ended 30 June 2020 £'000
Utilisation	8,281	3,115
Subscription	942	806
Other	2,015	651
Total revenue	11,238	4,572

Revenue streams are analysed between Utilisation, Subscription and Other services as follows:

Utilisation revenue

- Individually purchased consultations: Revenue is recognised immediately upon completion of consultation. Where revenue arises from unutilised purchased consultations, this is recognised in Other revenue below.

Subscription revenue

- Monthly or Annual service subscription: Revenue is recognised evenly over the subscription period.

Other revenue

- Minimum number of purchased consultations: some customers purchase consultations as a bundle for a fixed amount which entitles them to a minimum number of consultations per period. At the end of the period and if the actual number of consultations is less than the minimum number in the bundle, the revenue in respect of the unutilised days is recognised in full.
- Technology platform licencing: revenue is deferred and recognised evenly over time, over the period of which the licence is granted.
- Digital design services: revenue is recognised at a point in time, when the performance obligation, the delivery of customised software applications to the customer, is complete.

A **contract asset** is recognised for revenue where the performance obligation (being the provision of utilisation and subscription services) has been completed, but payment remains conditional on acceptance by the customer. Once invoiced, the amount recognised as contract assets is reclassified to trade receivables.

A **contract liability** is recognised if a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services or for instances where the customer is invoiced in advance. Contract liabilities are recognised as revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer). Contract liabilities arise from annual service subscriptions and technology platform licencing.

4. Segmental reporting

The Group provides virtual healthcare services, technology platform licencing and digital design services, within the United Kingdom. While revenue streams can be analysed by the nature of the service provided, the centralised common infrastructure means that operating costs are not and cannot meaningfully be allocated to the separate revenue streams. The chief operating decision-maker of the Group is the Chief Executive Officer, who has Group-wide functional, rather than product-related responsibilities. As a result, resources are allocated and performance is assessed by the chief operating decision-maker on the basis of the business as a whole.

5. Administrative expenses

	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Operating Costs	2,374	1,225
Research and Development	2,175	770
Sales and Marketing	1,574	593
General and Administration	7,825	4,926
	13,948	7,514

Operating Costs include the expenses attributable to the delivery of the Group's core services.

Research and Development include the expenses attributable to the development and maintenance of the Group's intellectual property.

Sales and Marketing include the expenses attributable to the selling and marketing of the Group's services.

General and Administration include the expenses attributable to supporting the Group's operating functions, depreciation, amortisation and share-based payments.

6. Other Operating Income

Other operating income reported in the Interim Condensed Consolidated Statement of Comprehensive Income consists of the following:

	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Profit on partial disposal of subsidiary	–	4,964
Recharges to joint venture	305	–
Foreign exchange gains	(51)	–
	254	4,964

In January 2020, the Company partially disposed of a subsidiary, Doctor at Hand Diagnostics Limited (formerly Internet Hospital Limited), through a sale of 50% of the issued share capital to AXA PPP for total consideration of £3 million. In advance of this partial disposal certain intangible assets created within the group were transferred to Doctor at Hand Diagnostics Limited. The remaining investment of 50% is now accounted for as an investment in joint venture.

Notes to the Interim Condensed Consolidated Financial Statements cont.

The fair value of assets disposed of, and the consideration received, were as follows:

	£'000
Intangible assets	1,057
Debtors and other assets	4
Bank balances and cash	8
Current liabilities	(1)
Non-current liabilities	(32)
Net assets disposed	1,036
Recognised as investment in joint venture	(3,000)
	(1,964)
Profit on disposal	4,964
Total consideration	3,000
Bank balances and cash	(8)
Net cash inflow in period	2,992

The fair value of the remaining investment of 50% was determined with reference to the amount that a third party, AXA Health, paid for a 50% interest in the company in an arm's length transaction.

Total consideration constituted £1 received at the date of disposal in January 2020. Deferred consideration of £2,999,999 was received in March 2020.

The amount recognised as a gain attributing to measuring the investment retained at its fair value was £1,489,249.

Operating income reported in the Interim Condensed Consolidated Statement of Comprehensive Income for the period ended 30 June 2020 relating to this transaction consists of:

	£
Profit of partial disposal of subsidiary	4,964

7. Operating loss

The operating loss is stated after charging:

	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Cost of sales employee costs	4,282	891
Cost of sales contractor costs	1,168	1,154
Administrative expenses employee costs	9,317	4,581
Administrative expenses contractor costs	589	890
Depreciation	243	145
Amortisation of intangible assets	291	509
Exchange difference	51	2

Employee costs consist of:

	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Wages and salaries	11,549	4,846
Social security costs	1,311	570
Costs of defined contribution scheme	146	53
Share-based payment	593	2
	13,599	5,472

8. Finance costs

Finance costs consist of the following:

	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Fair value remeasurement on convertible loan notes (see note 16 below)	–	18,537
IFRS 16 lease liability charge	71	3
Loan interest	1	–
	72	18,540

The credit risk component in the fair value remeasurement on convertible loan notes is deemed to be immaterial by the Directors of the Group. Therefore, this component has not been separately disclosed within Other Comprehensive Income.

9. Income tax

The Group calculates the income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the interim condensed consolidated statement of comprehensive income are as follows:

	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Income taxes		
Current income tax credit	50	61

Notes to the Interim Condensed Consolidated Financial Statements cont.

10. Earnings per Share (EPS)

Basic EPS is calculated by dividing the total comprehensive loss for the period attributable to equity holders of the parent by the weighted average number of equity shares outstanding during the period.

Diluted EPS is calculated by dividing the total comprehensive loss for the period attributable to equity holders of the parent (after adjusting for potential inflows/outflows on all dilutive potential shares) by the weighted average number of equity shares outstanding during the period plus the weighted average number of equity shares that would be issued on conversion of all the dilutive potential equity shares into equity shares.

There is no difference in the total comprehensive loss for the period or the weighted average number of equity shares used for the calculation of basic and diluted loss per share, as the effect of all potentially dilutive shares outstanding was anti-dilutive.

In November 2020, the Group undertook a sub-division of its shares on a 6:1 basis, the following table reflects the income and share data used in the basic and diluted EPS calculations and is adjusted to reflect the position if the sub-division had taken place on 1 January 2020:

	Period ended 30 June 2021 Unaudited £'000	Period ended 30 June 2020 Unaudited £'000
Total comprehensive loss for the year	8,042	18,662
Weighted number of equity shares:		
Ordinary shares	327,183,012	45,496,294
A1 preferred shares	–	60,939,462
A2 preferred shares	–	90,910,032
Weighted number of equity shares: for calculation of Basic and Diluted EPS	327,183,012	197,345,789
Loss per share	£	£
Basic and diluted	0.02	0.16

11. Property, plant and equipment

During the six months ended 30 June 2021, the Group acquired computer equipment and office furniture with a cost of £328,953 (30 June 2020: £156,447).

12. Intangible assets

During the six months ended 30 June 2021, the Group capitalised software development costs of £904,998 (30 June 2020: £1,095,807). Software development costs with a net book value of £1,057,324 were transferred by the Group into Doctor at Hand Diagnostics Limited during the six months ended 30 June 2020, as part of the partial disposal discussed in note 6 above.

The Directors assess intangible assets for impairment when there is an indicator of impairment or on at least an annual basis. The Directors have not identified during the period any indicators of impairment for intangible assets.

13. Interest in joint venture

As explained in note 6 above, following the partial disposal of 50% of the Group's investment in Doctor at Hand Diagnostics Limited, the remaining investment of 50% is now accounted for as an investment in joint venture. A joint venture is an arrangement in which the Group has joint control, whereby the Group has rights to the net assets of the arrangement, rather than rights to its assets and obligations for its liabilities. Interests in the joint venture are accounted for using the equity method. They are initially recognised at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Group's share of the profit or loss and OCI of equity accounted investees, until the date on which significant influence or joint control ceases. Movement in the Group's investment in joint venture during the financial period was as follows:

	Unaudited £'000
Recognised as investment in joint venture on partial disposal of subsidiary	3,000
Share of loss of joint venture from 31 January to 30 June 2020	(158)
Share of loss of joint venture from 1 July to 31 December 2020	(655)
Balance as at 31 December 2020	2,187
Share of loss of joint venture from 1 January to 30 June 2021	(144)
Balance as at 30 June 2021	2,043

14. Trade and other receivables

The following balances are all due to be realised within one year of the reporting date:

	As at 30 June 2021 Unaudited £'000	As at 31 December 2020 Audited £'000
<i>Assets held at amortised cost</i>		
Trade receivables	1,876	1,646
Other receivables	143	160
Prepayments	782	1,614
Contract assets	44	31
	2,845	3,451

Notes to the Interim Condensed Consolidated Financial Statements cont.

15. Trade and other payables: Amounts falling due within one year

	As at 30 June 2021 Unaudited £'000	31 December 2020 Audited £'000
<i>Liabilities held at amortised cost</i>		
IFRS 16 lease liability <1 year	274	286
Trade payables	898	688
Other taxation and social security	832	1,038
Other payables	45	48
Accruals	2,318	1,405
Contract liabilities	200	311
	4,567	3,776

16. Trade and other payables: Amounts falling due after one year

	As at 30 June 2021 Unaudited £'000	31 December 2020 Audited £'000
<i>Liabilities held at amortised cost</i>		
IFRS 16 lease liability >1 year	958	1,205
	958	1,205

17. Financial instruments

As at 30 June 2021 the Group has the following financial assets and financial liabilities:

	30 June 2021 Unaudited £'000	31 December 2020 Audited £'000
Financial assets		
<i>Current assets</i>		
<u>Held at amortised cost:</u>		
Cash and cash equivalents	31,472	38,362
Other financial assets	2,019	1,806
Total assets held at amortised cost	33,491	40,168
Financial liabilities		
<i>Current liabilities</i>		
<u>Held at amortised cost:</u>		
Financial liabilities	3,535	2,427
	3,535	2,427
<i>Non-current liabilities</i>		
<u>Held at amortised cost:</u>		
Financial liabilities	958	1,205
	958	1,205

Contract assets and liabilities under the scope of IFRS 15, and tax and social security balances, are not considered financial instruments and are excluded from the table above.

Notes to the Interim Condensed Consolidated Financial Statements cont.

18. Share options

The Group grants share options to certain members of the Company's employees. The options have a range of vesting periods and exercise conditions.

The share-based payment charge included in the profit and loss account for the six months ended 30 June 2021 was £592,918 (30 June 2020: £2,763). Expense in respect of the third and final tranche of the Chairman and CEO's performance options will be recognised when the scheme is updated to accommodate practical five-year expiry terms.

In November 2020 the Group undertook a sub-division of its shares on a 6:1 basis, the following table reflects the number of share options and the weighted average exercise price outstanding during the period and is adjusted to reflect the position if the sub-division had taken place on 1 January 2020:

	Weighted average exercise price (£) Period ended 30 June 2021 Unaudited	Number Period ended 30 June 2021 Unaudited	Weighted average exercise price (£) Period ended 30 June 2020 Unaudited	Number Period ended 30 June 2020 Unaudited
Outstanding at beginning of the period	0.35	31,252,374	0.11	2,807,273
Granted during the period	–	–	–	–
Exercised during the period	0.09	165,255	–	–
Lapsed during the period	0.33	3,600,000	–	–
Outstanding at the end of the period	0.36	27,487,119	0.11	2,807,273
Exercisable at the end of the period	0.20	7,908,491	0.11	2,742,321

The range of exercise prices in respect of options outstanding at 30 June 2021 is £0.05 to £0.59 (30 June 2020: £0.05 to £0.25). The weighted average remaining contractual life of outstanding options at 30 June 2021 is 6.6 years (30 June 2020: 7.9 years).

19. Events after the reporting period

There were no significant events after the reporting period.

Directors' Declaration

In the directors' opinion:

- a. the financial statements and notes set out on pages 6 to 18 are in accordance with the Corporations Act 2001, including:
 - i) complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
 - ii) giving a true and fair view of the consolidated entity's financial position as at 30 June 2021 and of its performance for the half-year ended on that date; and
- b. there are reasonable grounds to believe that Doctor Care Anywhere Group PLC will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



Jonathan Baines
Chairman and Executive Director
Doctor Care Anywhere Group PLC

London
Date: 17 August 2021



Dr Bayju Thakar
Chief Executive Officer and Managing Director
Doctor Care Anywhere Group PLC

London
Date: 17 August 2021

Independent Review Report to Doctor Care Anywhere Group PLC

Introduction

We have reviewed the consolidated condensed set of financial statements in the half-yearly financial report of Doctor Care Anywhere Group plc (the 'company') for the six months ended 30 June 2021 which comprises the consolidated statement of comprehensive income, consolidated statement of financial position, consolidated statement of changes in equity, consolidated statement of cash flows and related notes. We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial information.

Directors' responsibilities

The half-yearly financial report is the responsibility of, and has been approved by, the directors.

As disclosed in the notes, the annual financial statements of the company are prepared in accordance with International Financial Reporting Standards in conformity with the requirements of the Companies Act 2006. The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting'.

Our responsibility

Our responsibility is to express a conclusion to the company on the consolidated condensed set of financial statements in the half-yearly financial report based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The impact of uncertainties arising from the UK exiting the European Union on our review

Our review of the condensed set of financial statements in the half-yearly financial report requires us to obtain an understanding of all relevant uncertainties, including those arising as a consequence of the effects of Brexit. Such reviews assess and challenge the reasonableness of estimates made by the directors and the related disclosures and the appropriateness of the going concern basis of preparation of the financial statements. All of these depend on assessments of the future economic environment and the company's future prospects and performance.

Brexit is one of the most significant economic events for the UK, and at the date of this report its effects are subject to unprecedented levels of uncertainty, with the full range of possible outcomes and their impacts unknown. We applied a standardised firm-wide approach in response to these uncertainties when assessing the company's future prospects and performance. However, no review of interim financial information should be expected to predict the unknowable factors or all possible future implications for a company associated with a course of action such as Brexit.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2021 is not prepared, in all material respects, in accordance with International Accounting Standard 34, 'Interim Financial Reporting'.

Grant Thornton UK LLP

Grant Thornton UK LLP
Statutory Auditor, Chartered Accountants
London
17 August 2021

Corporate Directory

Directors

Jonathan Baines

Chairman and Executive Director

Dr Bayju Thakar

Chief Executive Officer and Managing Director

Romana Abdin

Independent Non-Executive Director

Simon Calver

Non-Executive Director

Richard Dammery

Independent Non-Executive Director

David Ravech

Non-Executive Director

Leanne Rowe

Independent Non-Executive Director

Vanessa Wallace

Independent Non-Executive Director

Company Secretary

Dan Curran

Chief Financial Officer and Company Secretary

Principal Registered Office in the United Kingdom

13–15 Bouverie Street
2nd Floor
London, England, EC4Y 8DP

Share Register

Computershare Investor Services Pty Ltd
452 Johnston Street
Abbotsford VIC 3067
Ph: +61 3 9415 4000

Auditor

Grant Thornton UK LLP
30 Finsbury Square
London
EC2A 1AG

Stock Exchange Listing

Doctor Care Anywhere Group PLC shares are listed on the Australian Securities Exchange (Listing code: DOC)

Website

www.doctorcareanywhere.com

UK Company Number and ARBN

Company Number: 08915336

ARBN: 645 163 873

